1. Home
  2. ABP vs MBAI Comparison

ABP vs MBAI Comparison

Compare ABP & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABP

Abpro Holdings Inc

HOLD

Current Price

$2.61

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.49

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ABP
MBAI
Founded
2004
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
10.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ABP
MBAI
Price
$2.61
$1.49
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.5K
23.7K
Earning Date
02-10-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
50.00
N/A
52 Week Low
$2.50
$0.59
52 Week High
$40.78
$3.13

Technical Indicators

Market Signals
Indicator
ABP
MBAI
Relative Strength Index (RSI) 25.89 N/A
Support Level $3.82 N/A
Resistance Level $3.33 N/A
Average True Range (ATR) 0.39 0.00
MACD -0.13 0.00
Stochastic Oscillator 2.45 0.00

Price Performance

Historical Comparison
ABP
MBAI

About ABP Abpro Holdings Inc

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: